Currently, the European Research Initiative for CLL (ERIC) recommends an enlarged panel of monoclonal antibodies (including CD43, CD79b, CD81, CD200, CD10, and ROR1) for the initial characterization, differential diagnosis and follow up of minimal residual disease [21,22]. The gene discussed is CD81; the disease is B-cell chronic lymphocytic leukemia.